1.85
Schlusskurs vom Vortag:
$1.85
Offen:
$1.83
24-Stunden-Volumen:
2.64M
Relative Volume:
0.37
Marktkapitalisierung:
$16.87M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.07M
KGV:
-0.1322
EPS:
-13.99
Netto-Cashflow:
$-12.56M
1W Leistung:
+9.52%
1M Leistung:
+207.69%
6M Leistung:
+164.06%
1J Leistung:
-46.04%
Palisade Bio Inc Stock (PALI) Company Profile
Firmenname
Palisade Bio Inc
Sektor
Branche
Telefon
(858) 704-4900
Adresse
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Vergleichen Sie PALI mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
PALI
Palisade Bio Inc
|
1.85 | 226.74M | 0 | -14.07M | -12.56M | -13.99 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Palisade Bio Inc Aktie (PALI) Neueste Nachrichten
Price action breakdown for Palisade Bio Inc.Market Rally & Long-Term Growth Stock Strategies - newser.com
Sector ETF performance correlation with Palisade Bio Inc.Portfolio Value Summary & Weekly Watchlist of Top Performers - newser.com
How moving averages guide Palisade Bio Inc. tradingMarket Trend Report & Growth Oriented Trading Recommendations - newser.com
Using data filters to optimize entry into Palisade Bio Inc.Quarterly Trade Summary & Growth Focused Entry Point Reports - newser.com
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108 - GlobeNewswire
Should I hold or sell Palisade Bio Inc. stock in 2025Market Activity Summary & Entry Point Strategy Guides - newser.com
What’s next for Palisade Bio Inc. stock pricePortfolio Gains Report & Risk Managed Investment Strategies - newser.com
Is Palisade Bio Inc. showing signs of accumulation2025 Volume Leaders & Growth Focused Entry Reports - newser.com
Palisade Bio Receives Canadian Patent for Composition of Product Candidate PALI-2108 - MarketScreener
Palisade Bio receives Canadian patent for inflammatory bowel drug - Investing.com
Palisade Bio Announces Grant of Patent for PALI-2108, a First-in-Class PDE4 Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis - Quiver Quantitative
PALI-2108 patent No. 3,174,137 protects drug through May 28, 2041 — Palisade Bio targets FSCD & UC - Stock Titan
What MACD and RSI say about Palisade Bio Inc.M&A Rumor & AI Based Trade Execution Alerts - newser.com
Will Palisade Bio Inc. stock recover after recent dropJuly 2025 EndofMonth & Free Low Drawdown Momentum Trade Ideas - newser.com
What analysts say about Palisade Bio Inc stockResistance Breakout Alerts & Rapid Portfolio Strategies - earlytimes.in
Palisade Bio Inc. stock trend outlook and recovery pathWeekly Market Report & Weekly High Conviction Trade Ideas - newser.com
Is Palisade Bio Inc. stock dividend yield sustainableMarket Rally & Free Community Supported Trade Ideas - newser.com
Palisade Bio, Inc. Cancels Special Meeting of Stockholders - TradingView
Palisade Bio Announces Cancellation of Special Meeting of Stockholders - GlobeNewswire
Special Meeting Cancelled: Palisade Bio Withdraws Proxy Proposals After Failing to Secure Quorum - Stock Titan
Cohen's Point72 Pours $14M in This Biotech Stock That… - inkl
Statistical indicators supporting Palisade Bio Inc.’s strengthMarket Trend Summary & Stepwise Swing Trade Plans - newser.com
How to forecast Palisade Bio Inc. trends using time seriesRate Cut & Reliable Intraday Trade Alerts - newser.com
Why Palisade Bio Inc. (7NS0) stock could outperform next yearJuly 2025 Reactions & Fast Exit/Entry Strategy Plans - newser.com
Ranking Palisade Bio Inc. among high performing stocks via toolsInsider Buying & Breakout Confirmation Trade Signals - newser.com
After-Hours Surge: Turn Therapeutics Rockets 134% Post-Close On Nasdaq Debut; Biotech Stocks Rally - RTTNews
Steven Cohen Doubles The S&P 500 — And His Next Bet's All Gut - Sahm
Biotech Stocks Surge After Hours: PCSA, PALI, And QTTB Lead On Volume And Speculation - Nasdaq
Is It Too Late to Buy Palisade Bio? - StocksToTrade
Palisade Bio Launches Phantom Unit Plan for Employees - MSN
Palisade Bio Stock Climbs To 9-Month High After $120M Stock Offering; Retail Sees More Gains Ahead - MSN
Morning Market Movers: FEMY, PALI, COSM, Seeing Big Swings - RTTNews
Morning Market Movers: SOPA, CRML, SANM, PALI See Big Swings - RTTNews
Is Palisade Bio Inc. stock bottoming outMarket Trend Report & Intraday High Probability Setup Alerts - newser.com
Understanding Palisade Bio Inc.’s price movementJuly 2025 Short Interest & Smart Money Movement Alerts - newser.com
Can Palisade Bio Inc. (7NS0) stock sustain breakout momentumJuly 2025 Drop Watch & Fast Moving Trade Plans - newser.com
Can technical indicators confirm Palisade Bio Inc.’s reversalJuly 2025 Price Swings & Daily Chart Pattern Signal Reports - newser.com
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Palisade Bio: Can It Balance the Volatility? - StocksToTrade
Published on: 2025-10-03 04:14:10 - newser.com
Using economic indicators to assess Palisade Bio Inc. potentialWeekly Profit Analysis & Weekly High Return Forecasts - newser.com
Published on: 2025-10-03 02:59:00 - newser.com
Palisade Bio (PALI) Stock Soars 30% on Securing $138M Public Offering Backed by Top Healthcare Players - parameter.io
Palisade Bio closes $138 million public offering for IBD drug development - Investing.com Nigeria
Finanzdaten der Palisade Bio Inc-Aktie (PALI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Palisade Bio Inc-Aktie (PALI) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Wei Binxian | Director |
Nov 21 '24 |
Option Exercise |
0.00 |
388 |
0 |
855 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):